The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal Cancer
Background: To analyze clinical, pathological and immunohistochemical correlates of survival in vaginal cancer patients. Methods: Retrospective analysis of primary vaginal cancer patients, treated at the Department of Gynecology and Gynecological Oncology of the University Hospital Bonn between 2007...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/4/1046 |
| _version_ | 1797621933145063424 |
|---|---|
| author | Eva K. Egger Mateja Condic Damian J. Ralser Milka Marinova Alexander Mustea Florian Recker Glen Kristiansen Thore Thiesler |
| author_facet | Eva K. Egger Mateja Condic Damian J. Ralser Milka Marinova Alexander Mustea Florian Recker Glen Kristiansen Thore Thiesler |
| author_sort | Eva K. Egger |
| collection | DOAJ |
| description | Background: To analyze clinical, pathological and immunohistochemical correlates of survival in vaginal cancer patients. Methods: Retrospective analysis of primary vaginal cancer patients, treated at the Department of Gynecology and Gynecological Oncology of the University Hospital Bonn between 2007 and 2021. Results: The study cohort comprised 22 patients. The median age was 63 years (range: 32–87 years). Squamous cell histology was present in 20 patients. Five-year OS in Stage I, II, III and IV was 100%, 56.25%, 0% and 41.67%, respectively (<i>p</i> = 0.147). Five-year DFS was 100%, 50%, 0% and 20.83%, respectively (<i>p</i> = 0.223). The 5-year OS was significantly reduced in the presence of nodal metastasis (<i>p</i> = 0.004), lymphangiosis (<i>p</i> = 0.009), hemangiosis (<i>p</i> = 0.002) and an age above 64 years (<i>p</i> = 0.029). Positive p 16 staining was associated with significantly improved OS (<i>p</i> = 0.010). Tumoral and immune cell PD-L1 staining was positive in 19 and in 16 patients, respectively, without significant impact on OS; 2 patients with metastastic disease are long-term survivors treated with either bevacizumab or pembrolizumab. Conclusion: P16 expression, absence of lymph- or hemangiosis, nodal negative disease and an age below 64 years show improved survival rates in PVC. Tumoral PD-L1 expression as well as PD-L1 expression on immune cells is frequent in PVC, without impacting survival. Within our study cohort, long-term survivors with recurrent PVC are treated with anti-VEGF and immunotherapy. |
| first_indexed | 2024-03-11T09:03:05Z |
| format | Article |
| id | doaj.art-76a0feb0cb75422e9b5561cf130bffa7 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T09:03:05Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-76a0feb0cb75422e9b5561cf130bffa72023-11-16T19:35:21ZengMDPI AGCancers2072-66942023-02-01154104610.3390/cancers15041046The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal CancerEva K. Egger0Mateja Condic1Damian J. Ralser2Milka Marinova3Alexander Mustea4Florian Recker5Glen Kristiansen6Thore Thiesler7Department of Gynecology and Gynecological Oncology, University Hospital, 53127 Bonn, GermanyDepartment of Gynecology and Gynecological Oncology, University Hospital, 53127 Bonn, GermanyDepartment of Gynecology and Gynecological Oncology, University Hospital, 53127 Bonn, GermanyDepartment of Nuclear Medicine, University Hospital, 53127 Bonn, GermanyDepartment of Gynecology and Gynecological Oncology, University Hospital, 53127 Bonn, GermanyDepartment of Gynecology and Gynecological Oncology, University Hospital, 53127 Bonn, GermanyDepartment of Pathology, University Hospital, 53127 Bonn, GermanyDepartment of Pathology, University Hospital, 53127 Bonn, GermanyBackground: To analyze clinical, pathological and immunohistochemical correlates of survival in vaginal cancer patients. Methods: Retrospective analysis of primary vaginal cancer patients, treated at the Department of Gynecology and Gynecological Oncology of the University Hospital Bonn between 2007 and 2021. Results: The study cohort comprised 22 patients. The median age was 63 years (range: 32–87 years). Squamous cell histology was present in 20 patients. Five-year OS in Stage I, II, III and IV was 100%, 56.25%, 0% and 41.67%, respectively (<i>p</i> = 0.147). Five-year DFS was 100%, 50%, 0% and 20.83%, respectively (<i>p</i> = 0.223). The 5-year OS was significantly reduced in the presence of nodal metastasis (<i>p</i> = 0.004), lymphangiosis (<i>p</i> = 0.009), hemangiosis (<i>p</i> = 0.002) and an age above 64 years (<i>p</i> = 0.029). Positive p 16 staining was associated with significantly improved OS (<i>p</i> = 0.010). Tumoral and immune cell PD-L1 staining was positive in 19 and in 16 patients, respectively, without significant impact on OS; 2 patients with metastastic disease are long-term survivors treated with either bevacizumab or pembrolizumab. Conclusion: P16 expression, absence of lymph- or hemangiosis, nodal negative disease and an age below 64 years show improved survival rates in PVC. Tumoral PD-L1 expression as well as PD-L1 expression on immune cells is frequent in PVC, without impacting survival. Within our study cohort, long-term survivors with recurrent PVC are treated with anti-VEGF and immunotherapy.https://www.mdpi.com/2072-6694/15/4/1046vaginal cancerimmunotherapyanti-VEGF-therapy |
| spellingShingle | Eva K. Egger Mateja Condic Damian J. Ralser Milka Marinova Alexander Mustea Florian Recker Glen Kristiansen Thore Thiesler The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal Cancer Cancers vaginal cancer immunotherapy anti-VEGF-therapy |
| title | The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal Cancer |
| title_full | The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal Cancer |
| title_fullStr | The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal Cancer |
| title_full_unstemmed | The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal Cancer |
| title_short | The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal Cancer |
| title_sort | role of p16 p53 ki 67 and pd l1 immunostaining in primary vaginal cancer |
| topic | vaginal cancer immunotherapy anti-VEGF-therapy |
| url | https://www.mdpi.com/2072-6694/15/4/1046 |
| work_keys_str_mv | AT evakegger theroleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT matejacondic theroleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT damianjralser theroleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT milkamarinova theroleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT alexandermustea theroleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT florianrecker theroleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT glenkristiansen theroleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT thorethiesler theroleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT evakegger roleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT matejacondic roleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT damianjralser roleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT milkamarinova roleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT alexandermustea roleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT florianrecker roleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT glenkristiansen roleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer AT thorethiesler roleofp16p53ki67andpdl1immunostaininginprimaryvaginalcancer |